News
-
-
-
COMMUNIQUÉ DE PRESSE
Gyala Therapeutics initiates Phase I/IIa clinical trial of a CAR-T cell therapy in acute leukemias with limited treatment options
Gyala Therapeutics starts Phase I/IIa trial of CAR-T cell therapy for acute leukemias, targeting CD84 protein. Study evaluates safety and efficacy in AML and T-ALL patients with limited options